Wire · opportunities
AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
AbbVie received FDA approval for Juvmo (tavapadon), a Parkinson's drug acquired from Cerevel Therapeutics in an $8.7 billion deal. The approval was supported by positive Phase 3 TEMPO program results showing significant improvements in motor symptoms and extended periods of good symptom control.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
You now face a fresh opportunity as Parkinson’s treatment options expand with Juvmo's approval. This shifts competitive pressure onto older therapies and opens new patient and provider engagement avenues.
◆ Coverage
5 sources · 28 Sep 2026
◆ Related on Wire
◆ Topics